

NEW BRUNSWICK DRUG PLANS FILGRASTIM / PEGFILGRASTIM SPECIAL AUTHORIZATION REQUEST

Please fax completed form to 506-867-4872 or 1-888-455-8322.

Request forms that are missing information will be returned for completion.

If no mailing address or fax number is provided, we will be unable to return a response.



Section 1 – Requestor Information		Section 2 – Patient Information	
First Name		First Name	
Last Name		Last Name	
Mailing Address (Street, City, Province, Postal Code)		Medicare Number (Critical for Processing) 1 2 3 4	456789
Telephone	Fax	Date of Birth (DD/MM/YYYY)	
Section 3 – Drug Requeste	ed		
Select one of the following: Filgrastim 300 mcg SC daily Filgrastim 480 mcg SC daily Filgrastim (specify dose):		Number of cycles required: Number of doses per cycle: OR Anticipated duration of therapy:	
Section 4 – Indication			
For Chemotherapy Support (Filgrastim or Pegfilgrastim) Chemotherapy is being administered with a curative intent: Yes No Indication (select one of the following): High risk of febrile neutropenia due to chemotherapy regimen, co-morbidities, or pre-existing severe neutropenia Febrile neutropenia, neutropenic sepsis or profound neutropenia in a previous cycle of chemotherapy Chemotherapy dose reduction, or treatment delay greater than one week due to neutropenia Other (please specify):			
For Non-malignant Indicatio Indication (select one of the fo To increase neutrophil cour cyclic neutropenia For the prevention and treat Other (please specify):	llowing): nt and reduce the incidence an	nd duration of infection in patients with congenital, into	diopathic or
For Stem Cell Transplantation	on Support (Filgrastim Only)		
Indication (select one of the fo	llowing): al blood progenitor cells for th	e purpose of stem cell transplantation	
Section 5 – Requestor's Signature			
Signature	ī	License or Registration Number Date (DD/I	MM/YYYY)

This information is collected under the authority of the *Prescription and Catastrophic Drug Insurance Act*, or the *Prescription Drug Payment Act*. This information will be used and disclosed to administer the NB Drug Plans (New Brunswick Prescription Drug Program and New Brunswick Drug Plan). It may be used and disclosed in accordance with the *Personal Health Information Privacy and Access Act*.